Mentari Taps M&A Veteran for CEO as Migraine Ambitions Grow

WALTHAM, MA – July 20, 2026 – In the high-stakes world of biotechnology, leadership appointments are rarely just about filling a vacancy. They are strategic signals, chess moves that telegraph a company's ambitions long before a product hits the market. The announcement from Mentari Therapeutics that Greg Divis will take the helm as CEO is precisely such a move. This isn't merely a leadership transition; it's a declaration of intent. By bringing in an executive renowned for navigating a company from the clinic to a multi-billion-dollar acquisition, Mentari is signaling that its promising migraine pipeline is on a trajectory not just for clinical success, but for significant commercial and corporate impact.

The appointment comes at a pivotal moment for the privately held company. While the press release focuses on Divis and the potential of its next-generation migraine therapies, the fine print reveals an even bigger story: a proposed merger with InMed Pharmaceuticals designed to take Mentari public, backed by a formidable $290 million war chest. This is a company gearing up for a fight, and it just hired a proven champion to lead the charge.

A Proven Finisher Takes the Helm

To understand the significance of Greg Divis's appointment, one need only look at his recent tenure at Avadel Pharmaceuticals. Divis took a development-stage company and transformed it into a fully integrated commercial organization. He spearheaded the successful development, FDA approval, and commercial launch of Lumryz®, a treatment for narcolepsy, a complex and challenging endeavor. But his work didn't stop there. He then orchestrated Avadel's sale to Alkermes in a deal valued at up to an astonishing $2.4 billion. This is the track record that has investors and industry observers paying close attention.

As Julianne Bruno, Chair of Mentari's Board and a Growth Partner at Fairmount, noted, "Greg brings proven experience to Mentari during its foundational period of growth. He is the ideal choice to lead as we rapidly advance MT-001 and MT-002 through clinical development." Her praise goes beyond standard corporate pleasantries, highlighting the dual mandate of a modern biotech CEO: "His experience successfully commercializing Lumryz® and delivering on the acquisition by Alkermes demonstrates his ability to build shareholder value while also delivering meaningful therapies for patients." This is the core of the strategy: value creation and patient impact are two sides of the same coin.

Divis himself is focused on the scientific opportunity, which he sees as a clear path to market disruption. "Mentari's approach to migraine prevention...represents an opportunity to deliver enhanced migraine relief for patients who continue to suffer with the current standard of care," he stated. His vision marries the clinical potential with commercial pragmatism, a combination that made him so successful at Avadel and so attractive to Mentari's board.

The Strategic Blueprint: A Merger and a War Chest

While the CEO appointment is the headline, the corporate machinery whirring in the background is just as crucial. Buried in the legalese of today's announcement is a reference to a proposed merger with InMed Pharmaceuticals. Research into SEC filings reveals this is a strategic reverse merger, a well-trodden path for a private biotech to gain access to public markets and the capital they hold. The combined entity will operate as Mentari Therapeutics and trade on the Nasdaq, effectively giving the company a public platform to fund its ambitious plans.

And those plans are well-funded. Concurrent with the merger, Mentari secured an oversubscribed $290 million private placement. The list of participants reads like a who's who of sophisticated biotech investment: Fairmount, a16z Bio + Health, Venrock Healthcare Capital Partners, Commodore Capital, and Blackstone, among others. This isn't speculative venture capital; it's a major infusion of growth-stage funding from investors who see a clear, multi-year path forward. The capital is projected to fund operations through 2028, providing a long runway to hit key clinical milestones for its lead assets.

This two-pronged strategy—a public listing via merger and a massive capital raise—is a textbook move to de-risk and accelerate development. It provides the financial firepower needed to run expensive clinical trials while giving the company the currency of public stock for future strategic moves. With Divis at the helm, an expert in M&A and shareholder value, the structure is perfectly aligned with the leadership.

Beyond CGRP: Redefining Migraine Prevention

The strategic and financial maneuvering is all in service of a powerful scientific idea. The migraine treatment landscape was revolutionized in recent years by the arrival of CGRP (calcitonin gene-related peptide) inhibitors. These drugs have provided relief for millions, but a significant portion of patients still experience incomplete responses, leaving a substantial unmet need. This is where Mentari aims to make its mark.

Mentari's pipeline is built around a different, but complementary, target: PACAP (pituitary adenylate cyclase-activating polypeptide). This pathway is mechanistically independent from CGRP but is also a validated driver of migraine attacks. The company's lead candidate, MT-001, is an anti-PACAP antibody designed for convenient subcutaneous dosing, with regulatory filings expected to support its advancement this year.

The real game-changer, however, may be MT-002. This is a bispecific antibody, a sophisticated piece of protein engineering that targets both the PACAP and CGRP pathways simultaneously. The hypothesis is that by blocking two key, complementary migraine signaling pathways, MT-002 could offer superior relief, especially for those who don't get the desired results from CGRP-only therapies.

"With MT-002 also designed for convenient subcutaneous delivery, Mentari is well-positioned to lead the next wave of migraine treatment," Divis commented, emphasizing both the scientific innovation and patient-centric design. The company is not just creating a 'me-too' drug; it is attempting to build a better, more comprehensive solution from the ground up. With regulatory filings for MT-002 slated for early 2027 and Phase 1 data expected later that year, the market will soon get its first glimpse of this dual-action approach in humans. The potential to deliver 'migraine freedom' is a lofty goal, but it is one grounded in a strong scientific rationale that has clearly captured the imagination of top-tier investors.